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Proper collection of infectious biosamples is critically important for better understanding of the disease pathogenesis and 
health. These precious samples are stored in biobanks. COVID-19 is an infectious disease caused by the recently discovered 
novel coronavirus named SARS-COV-2. Currently, specific drugs are not available against this virus though efforts on 
development of vaccines by various agencies have shown some positive results. Limited knowledge about the pathogenesis 
mechanism is a critical gap in developing intervention options. Access of COVID-19 biosamples for research could provide 
more insight into the disease. The Indian Council of Medical Research (ICMR) designated National Liver Disease Biobank 
(NLDB) as one of the dedicated facilities for collection and storage of COVID-19 biosamples for research purposes. 
Samples are collected, processed, and stored with proper security at NLDB. In this minireview, we have made an attempt to 
provide comprehensive coverage on the role of biobanking in Covid-19 pandemic. 
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Biobanking 
Biobanking is an important tool in biomedical 
research, which facilitates research in various fields 
by providing access of biological materials and 
associated clinical data1. In ancient times, biobanks 
were the way of the collection of samples and 
associated information. Samples were collected, 
processed, stored, and shared in the beginning without 
any regulations and rules. However, as the research 
field advanced, scientists stressed the use of high-
quality biological material. The requirement for the 
different type of samples (Oropharyngeal/naso-
pharyngeal swabs, bronchoalveolar lavage, sputum, 
blood, urine and stool) size, the procedure of sample 
collection, process, transportation, storage, and 
connected information became more specific and 
precise to study diseases and disorders. Biobanking 
represents a new and innovative field for development 
and discovery of new drugs2. 
Further, biobanks play a critical role in the 
diagnosis, classification of complex diseases, 
identification of new biomarkers, and development of 
treatments for a variety of diseases. International 
organizations like International Society for Biological 
and Environmental Repositories (ISBER), Biobanking 
and Bio-Molecular Resources Research Infrastructure 
(BBMRI) and government agencies involved in 
shaping biobanking practices3,4. These organizations 
are also engaged to provide scientific, ethical, and 
legal guidelines for pharmaceutical companies, the 
R&D sector, and healthcare. These units meet all 
requirements to regard them as one of the most 
innovative and up-to-date in the field of biomedical 
research. They enable conducting wide-scale research 
by the professional collection of biological specimens 
and correlated clinical data. 
COVID-19 
COVID-19 is an infectious disease caused by the 
most recently discovered SARS-CoV-2 (Severe Acute 
Respiratory Syndrome-Coronavirus-2). This new 
virus and conditions were unknown before the 
outbreak began in Wuhan, China, in December 2019. 
The World Health Organization (WHO) declared 
COVID-19 as a global pandemic on March 11, 2020. 
As of 29 December 2020, it has rapidly spread to 
more than 222 countries affecting 81,988,852 people 
and caused 1,787,759 deaths worldwide5. In India, 
there are 10,242,306 reported cases, with 148,423 
deaths6. The COVID cases are rising at an 
exponential rate. Due to absence of specific medicine, 
an increasing number of cases and associated 
mortality forced lockdowns in various countries to 
break the chain of the virus. Worldwide, scientists are 








Currently, more than 50 COVID-19 candidate 
vaccines are reported to be in trials7. Two vaccines, 
pfizer-biontech-covid-19-vaccine and moderna-covid-
19-vaccine, declared safe and authorized by FDA for 
emergency use, have been released for prevention of 
COVID-19 caused by SARS-CoV-2 in >16 years and 
>18 years, respectively in the second week of 
December 20208. 
 
Biobanking in COVID Pandemic 
Since, SARS-COV is an emerging pathogen of 
Risk Group 3 (RG3) category, the specimens 
collected from infected individuals should be handled 
carefully and follow standard guidelines of safety. For 
COVID-19 related research purposes, various types of 
samples should be collected including body fluids, 
epithelial tissues, secretions, and cells of the immune 
system. Precise collection of biosamples and its 
characterization with correlated data is important for 
the correct diagnosis, the origin of disease, 
epidemiological analyses, and understanding for the 
development of medicine/vaccine. 
 
In the past, an ample number of samples were 
stored in biobanks during various disease outbreak 
periods. These valuable samples were utilized for 
finding the history of infections, disease 
characterization, and development of epidemiological 
tools, e.g. Spanish flu pandemic of 1918-1919 
accounted somewhere between 20 to 40 million 
people, cited the worst infectious epidemic in world 
history. Preserved tissue from a victim of the 1918 
epidemic was used to determine the origin of the virus 
and allowed to track major genetic events of change9. 
Similarly, the 2014-2016 Ebola outbreak in Sierra 
Leone precipitated largescale biobanking of 
diagnostic samples, the research done on these 
biosamples contributed substantially to the knowledge 
and control of Ebola disease. The Centers for Disease 
Control and Prevention (CDC), United States has 
maintained a biobank of epidemic diseases for 
decades and found the source of outbreaks of 
Hantavirus and Legionnaires Disease10,11.  
 
Collection of COVID-19 biosamples would create 
a precious resource and provide a unique opportunity 
to facilitate the rapid expansion of our knowledge 
about the virus and its pathogenesis. Many countries 
worldwide have started COVID biobank to facilitate 
COVID-19 vaccine and/or treatment. Biobanking and 
Bio-Molecular Resources Research Infrastructure-
European Research Infrastructure Consortium 
(BBMRI-ERIC) is a European research infrastructure 
involved in facilitating quality defined COVID-19 
biosamples from its network of more than 600 
biobanks12. Table 1 provides the list of COVID 
biobanks across the world. 
 
SARS-COV-2 Biobanking at NLDB 
National Liver Disease Biobank (NLDB) is an 
advanced open resource facility established by the 
Department of Biotechnology, Government of India 
in 2017 at the Institute of Liver and Biliary Sciences 
(ILBS) to accelerate research in liver associated 
diseases13,14. Although, the NLDB is a liver disease 
biobank, the ICMR designated it as a centre for add-
on COVID biobank permitting it for collection of 
COVID-19 biosamples for research, developing 
diagnostics, and support vaccine development 
activities. ILBS is a center for COVID-19 testing 
laboratory designated by ICMR, Government of 
India. COVID-19 samples from seven government 
run and nineteen privately run hospitals for are 
accepted for testing at ILBS. It handles approximately 
300-400 tests per day. After collecting COVID 
samples from three hospitals, NLDB processes the 
samples in ‘state-of-the-art’ BSL 2 & 3 laboratories 
and stores them in ultra-freezer at 80C and LN2 
tanks, assigned for SARS-CoV-2. The process is 
explained in Fig. 1. The data is managed by Biobank 
Information Management System (BIMS), designed 
and developed by NLDB. At present, biobank have 
21,183 biosamples from 16,534 COVID-19 patients 
with well annotated clinical and follow-up data. 
 
NLDB is involved in multiple projects for 
collection of COVID biosamples in collaboration with 
different research institutes and hospitals. NLDB has 
a Biosample Release Committee (BRC) to review the 
scientific and ethical appropriateness of the proposed 
Table 1 — List of COVID biobank across the world 
Name of Biobank Types of samples Country 
UK Biobank Blood UK 
Biogen, Broad Institute 
of MIT and Harvard 
COVID-19 Biobank 
Blood USA 





eal swabs, bronchoalveolar 
lavage, sputum, blood, urine 
and stool 
India 
Joao Lobo Antunes 
Institute of Molecular 
Medicine Biobank 
Blood Portugal 
NSW Health Pathology 
COVID-19 Biobank 
blood, swabs Australia 
Biobank Graz Blood Austria 
 




projects for requisition and release of the biosamples 
along with clinical information. The process is  
explained in Fig. 2. Research institutes and pharma 
industries require standard samples and phenotypic 
characterization of the disease because of the 
Government of India and funding agencies’ initiative to 
grants to organizations or individuals who are focused 
on developing diagnostics, vaccines, novel therapeutics 
including the repurposing of existing drugs, and any 
other intervention for the control of COVID-1915.  
 
Challenges of COVID-19 Biobanking and Research 
 
Handling of COVID-19 sample 
Collection, transportation, processing, and storage 
of COVID-19 biospecimens, unlike other non-
infectious samples, biobanks must develop a separate 
SOP for COVID-19 biobanking. All biospecimens 
related to COVID-19 shall be collected and handled 
as per the ICMR guidelines for clinical samples under 
the strategy of COVID 19 testing in India16. Handling 
of COVID-19 samples are not possible for all 
biobanks and laboratories asit is necessary to have a 
BSL 2/3 laboratory due to the nature of work and 
samples. Biosamples must be handled by trained  
staff using the recommended Personal Protective 
Equipment (PPE) and waste management SOPs17. 
Personnel involved in COVID-19 biobanking should 
have a designated area for donning and doffing PPE. 
To minimize the risk of transmitting the virus and 
contaminating other samples, the workspace area 
should be away from the main lab. It is also essential 
that the transportation of biosamples should be under 
proper cold-chain conditions and with triple-layered 
packing. 
 
Ethical challenges  
During the infectious disease outbreak, it is 
incumbent that infected biosamples are stored and 
used for research. All research to be considered 
ethical with minimum risk and maximum benefit. 
Since the biosamples are property of patients, 
informed consent must be signed before storing the 
samples. At times, diagnostic leftover COVID-19 
samples, stored without informed consent, matter in 
ethics. It such cases the Institutional Review Board 
(IRB) also known as Ethical Review Board (ERB) or 
Research Ethics Board (REB) take a call and decide 
the use of biosamples in research and waive off of the 
otherwise mandatory requirement of informed 
consent. 
 
An effective digital meeting of the ethical 
committee is crucial for a rapid review of research 
proposals and protocols during the lockdown and to 
keep social distancing. IRB should make sure to 
maintain the quality of ethics committee decision-
making by avoiding any superficial decision, approval 
of poor-quality or extraneous research. 
 
Bioterrorism 
Terrorists are doing intentional violence with a 
different type of weapon for political or religious 
purposes. Bioterrorism agents are a common choice 
for them because they are inexpensive and can cause 
extensive effects. The international community has 
experienced multiple acts of bioterrorism from world 
war I to till date. In an earlier incidence, anthrax 
 
 
Fig. 1 — COVID-19 biobank work flow for collection,




Fig. 2 — COVID-19 biobank work flow for sample request,
review and release through Biosample Release Committee (BRC) 
 




spores was used as a bioweapon in America18. 
Regulating the possession, use, and transfer of 
biological agents (COVID-19) from the government 
by making strict rules and regulations could save a 
severe threat to public health and safety. 
 
Conclusion 
Biobanks are structured systems for collecting and 
storing valuable clinical samples. Access to high-
quality biosamples and data from COVID-19 infected 
patients is an essential requirement for the 
development and validation of new diagnostics, 
therapeutics, or vaccines. In this context, biobanks are 
a secure place for infectious biosamples and may play 
a critical crucial role in this pandemic. 
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